Page 102 - Immunization Practices News Today

Pending results of a CDC adcomm meeting, Pfizer said it anticipates vaccine supply availability in Q3 2023 ahead of the start of the 2023/24 RSV season this fall.

The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, RENOIR, demonstrating the RSV vaccine's efficacy, immunogenicity, and safety in adults 60 and older.

Hardly a week goes by that there is not yet another announcement of a hepatitis A positive employee putting co-workers, customers and the restaurant brand

NEW YORK - Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved ABRYSVO , the companys bivalent RSV prefusion F vaccine, for the prevention of lower respiratory... | June 1, 2023

The approval for Abrysvo represents the second RSV vaccine approved for adults aged 60 years and older in the last month.

The Commonwealth Healthcare Corp.’s Immunization Program will launch SMS text messaging reminders and notifications for people living in the CNMI on Saipan, Tinian, and Rota. The purpose of these messages is to encourage the community to stay up-to-date with their immunizations and vaccine/office information. This service will go live this week of May 29, 2023.

FDA’s decision is based on the data from the pivotal Phase 3 clinical trial in approximately 37,000 participants Each year in the U.S., it is estimated that between 60,000 and 160,000 older... | June 10, 2023

New evidence suggests the Centers for Disease Control and Prevention and U.S. Food and Drug Administration may have violated the Public Readiness and Emergency Preparedness Act when they withheld knowledge about myocarditis safety signals from...

Biden, McCarthy compromise over Debt Ceiling, Americans lose as Congress races to pass Bill Congressional reporter at The Hill Mychael Schnell discuss President Joe Biden and House Speaker Kevin Mc…

A man will receive the first of two Pfizer / BioNTech Covid-19 stitches on December 8, 2020 at Guy's Hospital in London.